An international study examining the currently available urine biomarker tests for bladder cancer showed variability in the sensitivities and specificities of all the tests and demonstrated “the importance of combining different approaches.”
According to study researcher Francois-Michel Boisvert, of Université de Sherbrooke, Canada, and colleagues, “absence of reliable screening methods, invasiveness of diagnostic modalities, and high recurrence rates, makes bladder cancer one of the most challenging and expensive cancers to diagnose and treat.”
Although cystectomy is considered the gold standard for disease diagnosis, it has limitations. In this study, Boisvert and colleagues examined the diagnostic accuracy of several urine-based tests used to diagnose bladder cancer in several different countries. They presented their findings at the European Society for Medical Oncology (ESMO) 2025 Congress.